下丘脑性肥胖市场（2026—2031）
下丘脑性肥胖市场规模预计由2026年的9.7亿美元增至2031年的15.1亿美元，预测期复合年增长率为9.23%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
下丘脑性肥胖市场规模预计由2026年的9.7亿美元增至2031年的15.1亿美元，预测期复合年增长率为9.23%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 9.23% | 机构预测 |
| 市场规模 | 2026 | USD 0.97 billion | 机构预测 |
| 市场规模 | 2031 | USD 1.51 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| care_setting | tertiary care hospitals | 2025 | 47.400% |
| etiology | craniopharyngioma-associated hypothalamic obesity | 2025 | 42.800% |
| geography | North America | 2025 | 41.300% |
| patient_group | pediatric patients | 2025 | 61.200% |
| treatment_type | nutritional and lifestyle management | 2025 | 36.500% |
关键结论
- care_setting 维度中，tertiary care hospitals 在 2025 年的公开份额为 47.4%。
- etiology 维度中，craniopharyngioma-associated hypothalamic obesity 在 2025 年的公开份额为 42.8%。
- geography 维度中，North America 在 2025 年的公开份额为 41.3%。
- patient_group 维度中，pediatric patients 在 2025 年的公开份额为 61.2%。
- treatment_type 维度中，nutritional and lifestyle management 在 2025 年的公开份额为 36.5%。
主要参与者
- Rhythm Pharmaceuticals, Inc.
- Saniona
- LG Chem Ltd.
- Novo Nordisk A/S
- Eli Lilly and Company
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Recognition of Hypothalamic Obesity as a Distinct Disease | +1.800% | Global, with early gains in North America and Western Europe | Short term (≤ 2 years) |
| Expansion of Disease-Specific MC4R Therapy | +2.800% | North America, European Union, and Japan | Short term (≤ 2 years) |
| Survivorship After Pediatric Brain Tumor Treatment | +1.500% | North America, Europe, and Asia-Pacific | Medium term (2-4 years) |
| Multidisciplinary Rare-Disease Care | +0.900% | North America and European Union, with expansion to Asia-Pacific | Medium term (2-4 years) |
| Earlier Postoperative Screening and Intervention | +0.600% | Europe and North America | Medium term (2-4 years) |
| Digital Hunger, Activity, and Weight Monitoring | +0.400% | North America, European Union, and Australia | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Limited Disease Recognition and Diagnostic Coding | -1.800% | Global, most acute in Asia-Pacific and South America | Short term (≤ 2 years) |
| Cost and Reimbursement Complexity of Specialty Therapies | -1.500% | North America and European Union, with broader access challenges | Medium term (2-4 years) |
| Fragmented Pediatric-to-Adult Care Continuity | -0.700% | Global, most pronounced without transition programs | Medium term (2-4 years) |
| Lack of Standardized Biomarkers and Long-Term Outcomes | -0.500% | Global | Long term (≥ 4 years) |
报告关注的关键问题
What is driving growth in hypothalamic obesity treatment?
IMCIVREE approvals, clearer diagnostic criteria, and greater survivorship after pediatric brain tumor treatment are supporting growth.
What is the projected growth rate for hypothalamic obesity treatment through 2031?
The overall category is forecast to grow at a 9.23% CAGR from 2026 to 2031.
Which cause accounted for the largest share in 2025?
Craniopharyngioma-associated hypothalamic obesity held 42.80% of the etiology mix in 2025.
Which treatment category is growing fastest?
Disease-specific pharmacological therapy is forecast to grow at an 18.40% CAGR through 2031.
Why are tertiary hospitals important for hypothalamic obesity care?
They held 47.40% of the care-setting mix in 2025 because diagnosis and treatment often require specialized multidisciplinary expertise.
Which region is forecast to grow fastest?
Asia-Pacific is forecast to grow at a 10.20% CAGR through 2031, supported by Japans 2026 authorization of IMCIVREE.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：高
查看来源：Mordor Intelligence